Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis

    loading  Checking for direct PDF access through Ovid


Background:The prognostic value of pretreatment systemic immune-inflammation index (SII) in lung cancer has yet to be fully established.Methods:Relevant articles were obtained by performing a systematic search. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to assess the relationship between SII index and overall survival (OS) in lung cancer; the OS was calculated from the time of cancer diagnosis to the date of death due to any cause or to the last date of follow-up.Results:In total, 2786 patients with lung cancer from 7 studies were included in this meta-analysis. The median thresholds to define high SII was 640 (range 395.4–1600) in the analyzed studies. The pooled HR for OS was 1.77 (95% CI: 1.54–2.00, P < .001), suggesting that the patients with a high SII score had a worse OS. In addition, results from subgroup meta-analysis showed the significant prognostic significance of SII in lung cancer. Especially, the predictive value of SII was significant in the multivariable model for NSCLC (HR: 1.97, 95% CI: 1.69–2.25, P < .001; 5 studies, 1746 patients), and SCLC (HR: 1.38, 95% CI: 1.02–1.85, P < .001; 1 study, 919 patients).Conclusion:Our data suggest that high SII index indicates poor survival rate in lung cancer. Further researches are warranted to verify the significance of SII index in clinical practice.

    loading  Loading Related Articles